贝伐单抗治疗恶性胸腹腔积液临床疗效

Clinical efficacy of bevacizumab in treatment of malignant pleural and peritoneal effusion

目的探讨贝伐单抗胸腔或腹腔内灌注治疗恶性胸腹水的临床疗效。方法收集2012年5～8月间在我科治疗的6例恶性胸腹水患者,予以胸腔或腹腔内灌注贝伐单抗200 mg,分别1～3次,评价患者胸腹水控制情况、症状改善情况和毒副作用。结果 6例患者中,CR 1例,PR 3例,SD 2例,除1例腹水患者出现轻度肠粘连,对症治疗后恢复外,余病例均未发生明显的毒副反应。结论胸膜腔内或腹膜腔内注入贝伐单抗治疗癌性胸腹水疗效明确,可短时间内迅速控制胸腹水,争取尽早进行全身治疗机会,对不能接受全身化疗的患者起到姑息减症的效果,改善了患者的生活质量。并未发生静脉应用的相关并发症,在老年患者中仍安全有效。

Objective To investigate the clinical efficacy of bevacizumab perfusion in treatment of malignant pleural and peritoneal effusion.Methods From May 2012 to August 2012,6 cases of patients with malignant pleural and peritoneal effusion in our department were perfused with bevacizumab 200mg into thorax or abdominal cavity,respectively 1-3 times.The control status of pleural and peritoneal effusion,improvement of symptoms and toxic or side effects were evaluated.Results Among 6 patients,there was 1 case of CR,3 cases of PR and 2 cases of SD,except for 1 patient with ascites had mild intestinal adhesion and recovered after symptomatic treatment,the remaining cases showed no obvious toxic and adverse reaction.Conclusion The efficacy of bevacizumab in treatment of malignant pleural and peritoneal effusion is definite,it can control hydrothorax and ascites in a short time,win over opportunity for early systemic treatment,appease and relieve symptoms in patients who cannot be treated with systemic chemotherapy,and improve the patient＇s quality of life.No complications related to intravenous application of bevacizumab has occurred,it is still safe and effective in elderly patients.